Skip to main content
. 2016 Sep 10;6(12):2084–2098. doi: 10.7150/thno.13917

Figure 4.

Figure 4

18F-FMISO MicroPET/CT imaging of U87MG tumor-bearing mice, IHC staining for CA-IX of tumor tissues and the relevant quantitative and correlation analysis. (A) Representative MicroPET/CT images at 1.0 h after intravenous injection of 18F-FMISO (5.55 MBq per mouse) on days 0, 1, 3, 7 and 13 post treatment. (B, C) Quantitative %ID/gmax of tumor uptake and the ratios of tumor to contralateral muscle (T/M) in the sunitinib and control groups based on ROIs analysis from 18F-FMISO MicroPET/CT. (D, E) IHC and quantitative analysis of tumor sections about CA-IX. (F) Correlations between 18F-FMISO T/M and CA-IX expression of tumor. Notes: The tumors were indicated by arrows. * P < 0.05, ** P < 0.01, within the sunitinib group, compared to day 0. + P < 0.05, + + P < 0.01, within the control group, compared to day 0. # # P < 0.01, between the sunitinib group and the control group.